780 related articles for article (PubMed ID: 12701114)
21. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
22. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma.
Kim Y; Weiss LM; Chen YY; Pullarkat V
Leuk Res; 2007 Dec; 31(12):1749-54. PubMed ID: 17544505
[TBL] [Abstract][Full Text] [Related]
23. Detection of the KIT
Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
[TBL] [Abstract][Full Text] [Related]
24. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
[TBL] [Abstract][Full Text] [Related]
25. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
26. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
28. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
29. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.
Beghini A; Ripamonti CB; Cairoli R; Cazzaniga G; Colapietro P; Elice F; Nadali G; Grillo G; Haas OA; Biondi A; Morra E; Larizza L
Haematologica; 2004 Aug; 89(8):920-5. PubMed ID: 15339674
[TBL] [Abstract][Full Text] [Related]
30. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
Valent P; Sperr WR; Schwartz LB; Horny HP
J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
[TBL] [Abstract][Full Text] [Related]
33. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
[TBL] [Abstract][Full Text] [Related]
34. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
36. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
Pullarkat ST; Pullarkat V; Lagoo A; Brynes R; Weiss LM; Bedell V; Chen W; Huang Q; Gaal K; Weisenburger DD; Kim YS
Leuk Res; 2013 Nov; 37(11):1572-5. PubMed ID: 24035334
[TBL] [Abstract][Full Text] [Related]
37. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
[TBL] [Abstract][Full Text] [Related]
38. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938
[TBL] [Abstract][Full Text] [Related]
39. Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) in an infant patient.
Kawakami T; Haga T; Soma Y; Nagae C; Kinoshita A
J Dermatol; 2014 Aug; 41(8):761-3. PubMed ID: 25099159
[No Abstract] [Full Text] [Related]
40. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
